Journal of Hospital Infection
|
|
- Chrystal Wilson
- 6 years ago
- Views:
Transcription
1 Journal of Hospital Infection xxx (2011) 1e5 Available online at Journal of Hospital Infection journal homepage: Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France K. Miliani a,f.l Hériteau a, L. Lacavé a, A. Carbonne a, P. Astagneau a,b, * on behalf of the Antimicrobial Surveillance Network Study Group 1 a Regional Coordinating Centre for Nosocomial Infection Control (C-CLIN Paris-Nord), Paris, France b Department of Public Health, Pierre et Marie Curie University School of Medicine, Paris, France article info summary Article history: Received 11 June 2010 Accepted 26 November 2010 Available online xxx Keywords: Antimicrobial resistance Ciprofloxacin consumption France Hospital antimicrobial consumption Imipenem consumption Resistant P. aeruginosa In France, Pseudomonas aeruginosa is the third most common isolate from nosocomial infections. To determine whether high consumption rates of some antibiotics are risk factors for resistance to ceftazidime, imipenem, ciprofloxacin and amikacin in P. aeruginosa, we conducted a study based on data from the Antimicrobial Surveillance Network in northern France and the French public reporting system of infection control indicators. These data were related to hospital characteristics (size, type, proportion of non-acute care beds), antibiotic consumption, incidence rates of some key resistances and quality indicators of healthcare-associated infection (HAI) control. In univariate analysis, high total and specific antibiotic consumption (except amoxicillin/clavulanate and imidazoles) were associated with high P. aeruginosa resistance rates. In multivariate analysis, high resistance rates were related to high imipenem and ciprofloxacin consumption [odds ratio (95% confidence interval): 7.9 (2.24e28.09), P < 0.05 for both], but were not significantly related to quality indicators of HAI control. These findings suggest that imipenem and ciprofloxacin use could play a major role in driving P. aeruginosa resistance, independent of other infection control performance. Ó 2011 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved. Introduction In France, Pseudomonas aeruginosa is the third most frequently isolated micro-organism from nosocomial infections. 1 This pathogen, naturally resistant to several antimicrobials, has a remarkable capacity for acquiring new resistance mechanisms under selective antibiotic pressure. 2,3 Resistance can result in treatment failure, increased morbidity and mortality (especially in critically ill patients), prolonged hospitalisation and higher healthcare costs. 4,5 Antimicrobial use is a risk factor for the development of antimicrobial resistance, but the relationship is complex. 2,3,6 From an ecological perspective, aggregate hospital data on antibiotic use * Corresponding author. Address: C-CLIN Paris-Nord, Site Broussais, Pavillon Leriche, 3e ETG, 96 rue Didot, Paris, France. Tel.: þ ; fax: þ address: pascal.astagneau@sap.aphp.fr (P. Astagneau). 1 Members: S. Alfandari, K. Blanckaert, C. Bonenfant, E. Bouvet, A. Chalfine, Y. Costa, E. Delière, F. Espinasse, N. Fortineau, Z. Kadi, J-L. Schmit, P. Votte. and bacterial resistance rates could be useful for researchers who study this relationship, and such data may be obtained as part of local or regional surveillance efforts. 6e9 Hence, as part of a multicentre hospital-based surveillance system in northern France, we conducted a study to determine whether high consumption rates of some antibiotics could be risk factors for high incidence rates of resistance by P. aeruginosa to ceftazidime, imipenem, ciprofloxacin and amikacin. Methods The study was based on data from the Antimicrobial Surveillance Network in northern France (described elsewhere 9 ) and the French public reporting system of infection control indicators (available online at URL: in The antimicrobial surveillance network, coordinated by the regional centre for nosocomial infection control in northern France (C-CLIN Paris Nord), was set up in 2002 with voluntary participation of healthcare facilities (HCFs). The main objective of the /$ e see front matter Ó 2011 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved. doi: /j.jhin
2 2 K. Miliani et al. / Journal of Hospital Infection xxx (2011) 1e5 network is to enable HCFs to monitor both antimicrobial consumption and antimicrobial resistance rates. It serves as a comparison tool allowing HCFs to recognise problems and improve the way in which antimicrobials are used. Furthermore, in 2005 the French Ministry of Health implemented an infection control indicators public reporting system for all HCFs in France as part of the French National Program for Prevention of Healthcare- Associated Infections (HAI) and Antimicrobial Resistance. 10 Five indicators were defined by a task group in 2003 and were progressively released through a multistep procedure of expert evaluation and validation. These indicators refer to structures, procedures and results in the field of HAI control. 10 Data collection Data regarding hospital characteristics and administrative data, antimicrobial consumption and incidence rates of resistant P. aeruginosa (ceftazidime-, imipenem-, ciprofloxacin- and amikacin-resistant) were obtained from the Antimicrobial surveillance Network for the 2007 surveillance period. These resistances were chosen in order to include one member of each of the four main classes of antipseudomonal agent. Data were retrospectively collected by the network with a standard protocol for all volunteer HCFs. In addition, for each participating HCF, the score attributed to three quality indicators of HAI control were extracted from the French public reporting system of infection control indicators for the 2007 year. Hospital characteristics and administrative data were captured regarding hospital type, hospital ownership and teaching status, type and number of beds and number of patient-days. Hospital-wide antimicrobial consumption of amoxicillin, amoxicillin/clavulanate, piperacillin/tazobactam, ceftazidime (CAZ), other third-generation cephalosporins, imipenem (IPM), ciprofloxacin (CIP), other fluoroquinolones, amikacin (AMK), other aminoglycosides, glycopeptides, macrolides, imidazoles and total consumption were collected and expressed in defined daily doses (DDDs) per 1000 patient-days according to the 2007 version of the Anatomical Therapeutic ChemicaleDDD classification from the World Health Organization. Data on bacterial resistance were provided by the laboratories serving the HCFs participating in the survey. Data included information on the number of isolates that were non-susceptible (intermediately susceptible and resistant) and the number of isolates tested for antimicrobial susceptibility from various consecutive clinical isolates (excluding those from stool cultures) of nosocomial P. aeruginosa. Antimicrobial susceptibility was interpreted in accordance with criteria recommended by the Antibiogram Committee update 2007 of the French Society for Microbiology (SFM). 11 We focused on P. aeruginosa resistant to CAZ, IPM, CIP, or AMK. The incidence rates of these resistances were expressed as the number of non-susceptible (intermediately susceptible and resistant) isolates per 1000 patient-days. Duplicate isolates from the same person were excluded. The quality indicators of HAI control used in our study were: (i) the composite score (scale: 0e100) measuring the development of the infection control structures and activities against nosocomial infections (ICALIN); (ii) the composite score (scale: 0e20) related to organisation of antibiotic use policy, the dedicated resources and activities (ICATB); and (iii) the percentage of target volume of hydro-alcoholic hand-rub products used in 2007 (in litres) per 1000 patient-days (ICSHA). 10 Data analysis Analysis focused only on HCFs that had antimicrobial susceptibility data for more than ten P. aeruginosa isolates. All variables were considered as categorical. The dependent variable has been dichotomised as: (1) HCFs with no resistance rates that exceed the 75th percentile (p75); and (2) HCFs with at least one resistance rate exceeding p75. Antibiotic consumption variables were divided into two classes according to 75th percentile (p75) in p75 or >p75 of overall distribution. The HCFs were classed according to type (public non-teaching, public teaching, private non-profit, private for-profit), size (<300 or 300 beds) and the proportion of nonacute care beds (i.e. the proportion of beds belonging to long term care, rehabilitation units or psychiatric wards in two classes <25% or 25%). The quality indicators were categorised according to the 25th percentile (p25) in p25 or >p25 of overall distribution. Univariate analysis was performed using Pearson c 2 -test and univariate logistic regression to obtain the crude odds ratios (ORs). Variables for which P 0.10 in the univariate analysis were included in a multivariate logistic regression model. A manual backward-stepwise variable-selection procedure was used. Variables remained in the multivariate model if the likelihood ratio test (e2ll) was significant (P 0.05). Akaike s information criterion (AIC) and the area under the receiver operating characteristic curve (ROC) were determined as measure of fit and discriminative accuracy, respectively. Statistical analysis was carried out using Stata statistical software, release 10.1 (Stata Corp., College Station, TX, USA). Results From 102 HCFs that participated in both surveys (antimicrobial consumption and antimicrobial resistance) in 2007, 84 tested more than 10 P. aeruginosa isolates and were included in the analysis. More than half (59.5%) of these HCFs were public, and among them 11 (13.1%) had teaching status, whereas 34 (40.5%) were private HCFs. Forty-three (51.2%) had <300 beds and 57 (67.9%) had 25% non-acute care beds. Most HCFs with <300 beds were private (69.8%), whereas almost all (90.2%) HCFs with 300 beds were public (teaching and non-teaching). Likewise, most HCFs with <25% of non-acute care beds were private (70.4%), whereas a similar percentage (73.7%) of HCFs with 25% non-acute care beds were public. A total of P. aeruginosa isolates were tested for antimicrobial susceptibility in the 84 HCFs included in analysis (median: 107 isolates per HCF; maximum: 2190). The numbers of isolates resistant to CAZ, IPM, CIP and AMK were 2462, 2967, 4253 and 2691, respectively. The median and interquartile ranges (IQR) of resistance rates are shown in Table I. Because aggregate data were obtained from each HCF, no information was available to determine whether isolates were multidrug resistant. Thirty (35.7%) HCFs had at least one key resistance rate >p75: seven (8.3%) HCFs had only one key resistance rate >p75; five (6.0%) had two key resistance rates >p75; five (6.0%) had three key resistance rates >p75 and 13 (15.4%) had all four key resistance rates >p75. The median overall antibiotic consumption was DDDs/ 1000 patient-days (IQR: 291.7e531.0). The highest levels were observed for penicillins and fluoroquinolones, with median consumptions of (150.8e305.6) and 53.5 (39.6e75.3) respectively. Amoxicillin and amoxicillin/clavulanate were the predominant penicillins, with median consumptions of 75.2 (42.9e102.8) and (85.4e191.3) respectively. Table I shows the median and IQR of antibiotic used for the comparisons as well as the median and IQR of the three quality indicators of HAI. In the univariate analysis (Table II), an incidence rate >p75 for at least one key P. aeruginosa resistance was associated (P < 0.10) with the type (public teaching hospitals and private non-profit) and structure (<25% of non-acute care beds) of HCFs, and with total and specific antibiotic consumption >p75 (except for amoxicillin/
3 K. Miliani et al. / Journal of Hospital Infection xxx (2011) 1e5 3 Table I Characteristic of study population (N ¼ 84 hospitals) Hospital characteristics Public non-teaching hospitals 39 (46.4%) Public teaching hospitals 11 (13.1%) Private non-profit 17 (20.25%) Private for-profit 17 (20.25%) Hospital size <300 beds 43 (51.2%) 300 beds 41 (48.8%) Proportion of non-acute care beds <25% 27 (32.1%) 25% 57 (67.9%) Quality indicators of HAI control a 2007 ICALIN score (range: 0e100) 98.0 (93.3e99.8) 2007 ICATB score (range: 0e20) 15.4 (12.5e17.4) 2007 ICSHA score (range: 0e100) 70.7 (49.6e93.5) Antimicrobial consumption (DDDs/1000 patient-days) a Amoxicillin 75.2 (42.9e102.8) Amoxicillin/clavulanate (85.4e191.3) Piperacillin/tazobactam 1.4 (0.1e3.6) Ceftazidime 1.7 (0.4e3.6) Other third generation cephalosporin 15.5 (8.7e25.9) Imipenem 1.7 (0.5e3.8) Ciprofloxacin 10.6 (5.9e21.6) Other fluoroquinolones 40.8 (22.5e53.0) Amikacin 3.0 (0.9e5.9) Other aminoglycosides 7.0 (2.9e14.4) Glycopeptides 4.5 (1.6e8.3) Macrolides 8.5 (4.3e15.4) Imidazoles 12.6 (5.5e21.5) Total consumption (291.7e531.0) Bacterial resistance rates (no. of non-susceptible isolates/1000 patient-days) a Ceftazidime resistance 0.15 (0.09e0.27) Imipenem resistance 0.11 (0.06e0.33) Ciprofloxacin resistance 0.26 (0.17e0.50) Amikacin resistance 0.15 (0.09e0.33) HAI, healthcare-associated infection; ICALIN, composite score measuring the development of the infection control structures and activities against nosocomial infections; ICATB, composite score related to organisation of antibiotic use policy; ICSHA, indicator of overall consumption of hydro-alcoholic hand-rub products; DDDs, defined daily doses. a Median (interquartile range). clavulanate and imidazoles, P ¼ 0.19 for each). Conversely, HCFs with an ICATB or ICSHA score <p25 were less likely to have high (>p75) resistance rates (P < 0.10). There were no associations with hospital size or ICALIN score <p25 (P ¼ 0.87 and P ¼ 0.79 respectively). In the multivariate analysis (Tables III and IV), after adjusting for the effect of the other variables included in the model (P < 0.10), high incidence rates (>p75) for at least one of the target resistances were related to high (>p75) IPM and CIP consumption (OR: 7.9; 95% confidence interval: 2.24e28.09; P < 0.05 for both). By contrast, P. aeruginosa resistance was not significantly related to low (<p25) alcohol hand-rub consumption ICSHA score (P ¼ 0.30) nor to a low (<p25) score for the quality indicator related to organisation of antibiotic use policy ICATB score (P ¼ 0.32). Discussion Our study found that high CAZ, CIP, IPM, or AMK resistance rates in P. aeruginosa were independently related to high IPM and CIP consumption. The emergence of antibiotic-resistant P. aeruginosa can be related to the overuse of several antimicrobial agents, although the risk appears to differ with different agents. 13e15 However, prior use of fluoroquinolones or IPM has been more Table II Univariate analysis: antibiotic agents and hospital characteristics related to high rates (>75th percentile) of at least one key resistance (ceftazidime, imipenem, ciprofloxacin or amikacin) among Pseudomonas aeruginosa isolates (N ¼ 84 hospitals) Variables At least one key resistance a with incidence rate >p75 (N ¼ 30) b Crude OR (95% CI) Antibiotic consumptions Piperacillin/tazobactam p75 (n ¼ 64) d 16 (25.0) >p75 (n ¼ 20) 14 (70.0) 7.0 (2.30e21.27) <0.001 Ceftazidime p75 (n ¼ 63) d 15 (23.8) >p75 (n ¼ 21) 15 (71.4) 8.0 (2.64e24.28) <0.001 Other 3rd generation Cephalosporins p75 (n ¼ 63) d 18 (28.6) >p75 (n ¼ 21) 12 (57.1) 3.3 (1.20e9.27) 0.02 Imipenem p75 (n ¼ 63) d 14 (22.2) >p75 (n ¼ 21) 16 (76.2) 11.2 (3.49e35.97) <0.001 Ciprofloxacin p75 (n ¼ 63) d 14 (22.2) >p75 (n ¼ 21) 16 (76.2) 11.2 (3.49e35.97) <0.001 Amikacin p75 (n ¼ 63) d 17 (27.0) >p75 (n ¼ 21) 13 (61.9) 4.4 (1.55e12.46) Glycopeptides p75 (n ¼ 63) d 17 (27.0) p75 (n ¼ 21) 13 (61.9) 4.4 (1.55e12.46) Total consumption p75 (n ¼ 63) d 16 (25.4) >p75 (n ¼ 21) 14 (66.7) 5.9 (2.02e17.13) Hospital characteristics Public non-teaching (n ¼ 39) d 8 (20.5) Reference Public teaching (n ¼ 11) 6 (54.6) 4.7 (1.13e19.21) Private non-profit (n ¼ 17) 11 (64.7) 7.1 (2.01e25.10) Private for-profit (n ¼ 17) 5 (29.4) 1.6 (0.44e5.93) Proportion of non-acute care beds <25% (n ¼ 27) 14 (51.9) 2.8 (1.071e7.14) % (n ¼ 57) d 16 (28.1) ICATB 2007 p25 (n ¼ 25) 5 (20.0) 0.3 (0.11e1.03) 0.05 p25 (n ¼ 59) d 25 (42.4) OR, odds ratio; CI, confidence interval; ICATB, composite score related to organisation of antibiotic use policy. Only variables significant at P 0.05 are shown. a Ceftazidime, imipenem, ciprofloxacin, or amikacin resistance among Pseudomonas aeruginosa isolates. b Data are expressed as number and percentage, n (%). c Pearson c 2 -test. d Reference class. frequently associated with P. aeruginosa resistance. In a cohort study, Carmeli et al. 12 found that IPM use was associated with emergence of resistance to IPM, CIP, CAZ and piperacillin/tazobactam in P. aeruginosa. In addition, piperacillin/tazobactam and CIP were related to the emergence of resistance to themselves, whereas CAZ was not. 12 Lepper et al., in a three-year survey of antimicrobial consumption and resistance in P. aeruginosa, found that IPM consumption was not only significantly associated with IPM resistance, but also with CAZ and piperacillin/tazobactam resistance. 13 No correlation was observed between CAZ or piperacillin/tazobactam consumption and resistance to themselves or to IPM. 13 Unlike previous studies, Mohr et al., at a single institution in an eight-year period, did not observe an association between IPM use and resistance in P. aeruginosa. 14 However, an increase in total fluoroquinolone use was associated with an increase in the P c
4 4 K. Miliani et al. / Journal of Hospital Infection xxx (2011) 1e5 Table III Factors associated with high incidence rates (>75th percentile) of at least one key resistance (ceftazidime, imipenem, ciprofloxacin or amikacin) among Pseudomonas aeruginosa isolates in the multivariate analysis Variables Full model Final model a Adjusted OR (95% CI) P Adjusted OR (95% CI) P Consumption Amoxicillin >p (0.34e13.94) 0.41 e e Piperacillin/tazobactam >p (0.15e16.80) 0.71 e e Ceftazidime >p (0.28e20.40) 0.43 e e Other 3rd generation 1.4 (0.18e10.46) 0.76 e e cephalosporin >p75 Imipenem >p (1.09e51.49) (2.24e28.09) Ciprofloxacin >p (1.41e34.27) (2.24e28.09) Other fluoroquinolone >p (0.68e19.12) 0.13 e e Amikacin consumption >p (0.12e5.52) 0.82 e e Other aminoglycoside >p (0.25e12.89) 0.55 e e Glycopeptide >p (0.04e5.18) 0.54 e e Macrolide >p (0.05e4.29) 0.51 e e Public non-teaching Reference e e e Public teaching 1.0 (0.10e10.26) 0.99 e e Private non-profit 3.2 (0.49e20.64) 0.23 e e Private for-profit 4.7 (0.59e37.00) 0.15 e e Proportion of non-acute 0.2 (0.03e2.00) 0.19 e e care beds <25% ICATB score 2007 p (0.07e2.38) 0.32 e e ICSHA score 2007 p (0.06e2.37) 0.30 e e OR, odds ratio; CI, confidence interval; ICATB, composite score related to organisation of antibiotic use policy; ICSHA, indicator of overall consumption of hydro-alcoholic hand-rub products. a Output model obtained by stepwise logistic regression analysis. Table IV Model validation results Variable Full model Final model No. of hospitals No. of hospital with at least one key resistance a rate >p75 e2ll b AIC Area under the ROC curve AIC, Akaike s information criterion; ROC, receiver operating characteristics. a Ceftazidime, imipenem, ciprofloxacin, or amikacin resistance among Pseudomonas aeruginosa isolates. b e2 log likelihood ratio test: c 2 ¼ 9.1 (degrees of freedom ¼ 15, P ¼ 0.87). incidence of IPM-resistant P. aeruginosa; a significant association between levofloxacin use and CIP resistance was also observed. 14 Our results emphasise the major role of IPM and CIP in P. aeruginosa resistance. 12,13,15 It should be noted that our study compared with preceding studies was hospital-based from a multicentre surveillance programme, and conducted with aggregate data on antibiotic consumption and P. aeruginosa resistance rates. It was carried out to determine whether high consumption rates of some antibiotics could be risk factors for HCFs having high incidence rates (>p75) of P. aeruginosa resistances (CAZ, IPM, CIP, or AMK resistance). Retrospective studies from multiple-hospital networks have found a positive association between increasing use of fluoroquinolones and fluoroquinolone-resistant P. aeruginosa. 16,17 Bhavnani et al. found that increasing expenditures of levofloxacin and ofloxacin, but not CIP, were associated with increased resistance rates to ciprofloxacin in P. aeruginosa. 17 Zervos et al. found a significant association between changes in fluoroquinolone use and changes in resistance in P. aeruginosa in 10 teaching hospitals from 1991 to During this period, fluoroquinolone usage increased by 97% in the participating hospitals. In our study we also collected information from the French public reporting system of infection control indicators regarding three quality indicators likely to measure the general performance of HAI control (ICALIN), antibiotic use policy (ICATB) and hydroalcoholic products consumption (ICSHA). No association was found between high resistance rates (>p75) among P. aeruginosa and the level of these quality indicators. In France, the implementation in 2005 of quality indicators that focus on the control of HAI was made on the assumption that an improvement of these indicators over time would be associated with a reduction in the burden of nosocomial infections. The development of these indicators was based on expert opinion and their public reporting mandated by the Ministry of Health. A recent population-based study in French hospitals found that a higher ICALIN score was significantly associated with a lower prevalence of meticillin-resistant Staphylococcus aureus infection, whereas ICSHA score was not 18 Further studies may be necessary to demonstrate and validate whether these indicators are the best measures to reduce rates of HAI. There are some limitations to our study. Selection bias cannot be excluded because HCFs participating in the antimicrobial network were not a random sample of HCFs in northern France and further studies will be required to determine whether the results are broadly applicable. Furthermore, no information was requested to determine whether isolates were resistant to more than one antibiotic or whether molecular investigation was performed to address the mechanisms by which resistance occurred. The causes of emergence and spread of antibiotic-resistant bacteria in HCFs are multifactorial including the high selective pressure that results from widespread use of antibiotics, particularly in intensive care units, cross-transmission from patient-to-patient, inappropriate or poor infection control measures, patient case-mix, inter-hospital transfer of resistance (clonal spreading of resistant bacteria or horizontal transfer of resistance genes), acquisition of organisms from the hospital environment, a community contribution of resistance, etc. 7,19e24 Nonetheless, because our data were extracted from a hospital-based multicentre surveillance system, it was not possible to obtain information on all potential confounders. For instance, the extracted data did not include data from specific wards for which local epidemiology and usage patterns for antibiotics could differ. Also, our data did not allow analysis of individual patient risk factors.
5 K. Miliani et al. / Journal of Hospital Infection xxx (2011) 1e5 5 Our study strongly suggests that use of IPM and CIP were related to high rates of resistance in P. aeruginosa, and therefore high consumption of IPM and CIP could play a major role in selective pressure exerted by antibiotics in P. aeruginosa strains. Acknowledgements We thank the members of the Antimicrobial Surveillance Network study group and all healthcare facilities for their participation in the Antimicrobial Surveillance Network. Conflict of interest statement None declared. Funding sources No specific funding has been received for this study. These data have been generated as part of the routine work of our Antimicrobial Surveillance Network. References 1. Thiolet J-M, Lacavé L, Jarno P, et al. Prévalence des infections nosocomiales, France, Bull Epidemiol Hebd 2007;51e52:429e Strateva T, Yordanov D. Pseudomonas aeruginosa e a phenomenon of bacterial resistance. J Med Microbiol 2009;58:1133e Mesaros N, Nordmann P, Plesiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13:560e Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrugresistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006;50:43e Lautenbach E, Synnestvedt M, Weiner MG, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010;31:47e Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999e2001). J Antimicrob Chemother 2004;53:290e Fridkin SK, Hill HA, Volkova NV, et al. Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals. Emerg Infect Dis 2002;8:697e Rogues AM, Dumartin C, Amadeo B, et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007;28:1389e Miliani K, L Heriteau F, Alfandari S, et al. Specific control measures for antibiotic prescription are related to lower consumption in hospitals: results from a French multicentre pilot study. J Antimicrob Chemother 2008;62:823e Carlet J, Astagneau P, Brun-Buisson C, et al. French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992e2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol 2009;30:737e Members of the SFM Antibiogram Committee. Comité de l antibiogramme de la société française de microbiologie report Int J Antimicrob Agents 2003;21: 364e Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43: 1379e Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002;46:2920e Mohr JF, Jones A, Ostrosky-Zeichner L, Wanger A, Tillotson G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-yearexperience: 1995e2002. Int J Antimicrob Agents 2004;24:346e Kang CI, Kim SH, Park WB, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005;11:68e Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991e2000. Clin Infect Dis 2003;37:1643e Bhavnani SM, Callen WA, Forrest A, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. Hospitals. Am J Health Syst Pharm 2003;60:1962e Grammatico-Guillon L, Thiolet JM, Bernillon P, Coignard B, Khoshnood B, Desenclos JC. Relationship between the prevalence of meticillin-resistant Staphylococcus aureus infection and indicators of nosocomial infection control measures: a population-based study in French hospitals. Infect Control Hosp Epidemiol 2009;30:861e Johnson JK, Smith G, Lee MS, et al. The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit. J Infect Dis 2009;200:900e Lepelletier D, Cady A, Caroff N, et al. Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn Microbiol Infect Dis 2010;66:1e Steinke D, Davey P. Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies. Clin Infect Dis 2001;33(Suppl. 3):S193e White RL, Friedrich LV, Mihm LB, Bosso JA. Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas. Clin Infect Dis 2000;31: 16e Pitten FA, Panzig B, Schroder G, Tietze K, Kramer A. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German university hospital. J Hosp Infect 2001;47:125e Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J Hosp Infect 1998;39:53e62.
Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationExecutive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts
Executive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts Investigational Team: Diane Brideau-Laughlin BSc(Pharm),
More informationStudies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India
Human Journals Research Article April 2016 Vol.:6, Issue:1 All rights are reserved by Zarine Khety et al. Studies on Antimicrobial Consumption in a Tertiary Care Private Hospital, India Keywords: Drug
More informationWorrying trends in antibiotic use in French hospitals,
vv v Worrying trends in antibiotic use in French, 2008-2013 C. Dumartin, A-M. Rogues, F. L Hériteau, M. Péfau, X. Bertrand, S. Boussat, H. Sénéchal, M. Giard, A. Ingels, L. Lacavé, L. Mouchot, A. Machut,
More informationAntibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
NEW MICROBIOLOGICA, 34, 291-298, 2011 Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units Vladimíra Vojtová 1, Milan Kolář 2, Kristýna Hricová 2, Radek Uvízl 3, Jan Neiser
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationStudy Protocol. Funding: German Center for Infection Research (TTU-HAARBI, Research Clinical Unit)
Effectiveness of antibiotic stewardship interventions in reducing the rate of colonization and infections due to antibiotic resistant bacteria and Clostridium difficile in hospital patients a systematic
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAntimicrobial stewardship
Antimicrobial stewardship Magali Dodemont, Pharm. with the support of Wallonie-Bruxelles International WHY IMPLEMENT ANTIMICROBIAL STEWARDSHIP IN HOSPITALS? Optimization of antimicrobial use To limit the
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationHow is Ireland performing on antibiotic prescribing?
European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationAerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune
Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationTandan, Meera; Duane, Sinead; Vellinga, Akke.
Provided by the author(s) and NUI Galway in accordance with publisher policies. Please cite the published version when available. Title Do general practitioners prescribe more antimicrobials when the weekend
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationEuropean Antibiotic Awareness Day
Initiating a pan-european health campaign - experiences from setting up the European Antibiotic Awareness Day Dr Ülla-Karin Nurm Head of Public Health Development Section, Public Health Capacity and Communication
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationAntimicrobial use in humans
Antimicrobial use in humans Ann Versporten Prof. Herman Goossens OIE Global Conference on the Responsible and Prudent Use of Antimicrobial Agents for Animals - 13 March 2013 - Ann.versporten@ua.ac.be Herman.goossens@uza.be
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationAntibiotic Susceptibilities of Pseudomonas aeruginosa Isolated from Blood Samples and Antibiotic Utilization in a University Hospital in Japan
Infect Dis Ther (2015) 4:213 218 DOI 10.1007/s40121-015-0066-x BRIEF REPORT Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolated from Blood Samples and Antibiotic Utilization in a University
More informationReceived: Accepted: Access this article online Website: Quick Response Code:
Indian Journal of Drugs, 2016, 4(3), 69-74 ISSN: 2348-1684 STUDY ON UTILIZATION PATTERN OF ANTIBIOTICS AT A PRIVATE CORPORATE HOSPITAL B. Chitra Department of Pharmacy Practice, College of Pharmacy, Sri
More informationClinical Usefulness of Multi-facility Microbiology Laboratory Database Analysis by WHONET
Special Articles Journal of General and Family Medicine 2015, vol. 16, no. 3, p. 138 142. Clinical Usefulness of Multi-facility Microbiology Laboratory Database Analysis by WHONET Sachiko Satake, PhD,
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union November 2012 Highlights on antibiotic consumption Antibiotic use is one of the main factors responsible for the development and
More informationVaccine Evaluation Center, BC Children s Hospital Research Institute, 950 West 28 th Ave,
Manuscript Click here to view linked References Age-specific trends in antibiotic resistance in Escherichia coli infections in Oxford, United Kingdom 2013-2014 Rebecca C Robey a, Simon B Drysdale b,c,
More informationSpecific control measures for antibiotic prescription are related to lower consumption in hospitals: results from a French multicentre pilot study
Journal of Antimicrobial Chemotherapy Advance Access published July 25, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn277 Specific control measures for antibiotic prescription are related
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationIs biocide resistance already a clinical problem?
Is biocide resistance already a clinical problem? Stephan Harbarth, MD MS University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland Important points Biocide resistance exists Antibiotic
More informationEFSA s activities on Antimicrobial Resistance
EFSA s activities on Antimicrobial Resistance CRL-AR, Copenhagen 23 April 2009 Annual Workshop of CRL - AR 1 Efsa s Role and Activities on AMR Scientific advices Analyses of data on AR submitted by MSs
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More information(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE
(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE John Ferguson (Hunter New England, NSW) on behalf of MRGN Task Force Acknowledgement
More informationRelationship Between Antibiotic Consumption and Resistance in European Hospitals
Relationship Between Antibiotic Consumption and Resistance in European Hospitals Dominique L. Monnet National Center for Antimicrobials and Infection Control, Statens Serum Institut, Copenhague, Danemark
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationAntimicrobial resistance (EARS-Net)
SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,
More informationAntimicrobial Stewardship Strategy: Dose optimization
Antimicrobial Stewardship Strategy: Dose optimization Review and individualization of antimicrobial dosing based on the characteristics of the patient, drug, and infection. Description This is an overview
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationESAC s Surveillance by Point Prevalence Measurements. by author
ESAC s Surveillance by Point Prevalence Measurements Herman Goossens, MD, PhD ESAC Co-ordinator VAXINFECTIO, Laboratory of Medical Microbiology University of Antwerp, Belgium Outline Background Point Prevalence
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationPrevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices
Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationRisk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case control study
Eur J Clin Microbiol Infect Dis (2010) 29:335 339 DOI 10.1007/s10096-009-0850-1 BRIEF REPORT Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double
More informationCouncil Conclusions on Antimicrobial Resistance (AMR) 2876th EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting
COUNCIL OF THE EUROPEAN UNION Council Conclusions on Antimicrobial Resistance (AMR) 2876th EMPLOYMT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting Luxembourg, 10 June 2008 The Council adopted
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationViResiST: its contribution to our knowledge of the relationship between antimicrobial use and resistance. Dominique L. Monnet
ViResiST: its contribution to our knowledge of the relationship between antimicrobial use and resistance Dominique L. Monnet About antibiotics... As soon as we use it, we loose it The more we use it, the
More informationJournal of Hospital Infection
Journal of Hospital Infection 75 () 23 27 Available online at www.sciencedirect.com Journal of Hospital Infection journal homepage: www.elsevierhealth.com/journals/jhin Impact of hospital-wide infection
More informationProtocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland
Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Version 1.0 23 December 2011 General enquiries and contact details This is the first version (1.0) of the Protocol
More informationWHO perspective on antimicrobial resistance
WHO perspective on antimicrobial resistance Bernadette Abela-Ridder, DVM, MSc, PhD Global Foodborne Infections Network (GFN) Coordinator Department of Food Safety and Zoonoses (FOS) 1 Overview of presentation
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationSurveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe
Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe Carl Suetens, ECDC Presented by Håkan Hanberger ecdc.europa.eu Message/Questions from C Suetens to Workshop 7, MIE2009
More informationExposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance
ORIGINAL ARTICLE BACTERIOLOGY Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance M. J. Cohen, C. S. Block, A. E. Moses and R. Nir-Paz Department of Clinical
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationIsolation of Urinary Tract Pathogens and Study of their Drug Susceptibility Patterns
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 4 (2016) pp. 897-903 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.504.101
More informationAntimicrobial Stewardship Program: Local Experience
Antimicrobial Stewardship Program: Local Experience Dr. WU Tak Chiu Associate Consultant Division of Infectious Diseases Department of Medicine Queen Elizabeth Hospital 18th January 2011 QUEEN ELIZABETH
More informationWhy should we care about multi-resistant bacteria? Clinical impact and
Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased
More informationInitiatives taken to reduce antimicrobial resistance in DK and in the EU in the health care sector
Initiatives taken to reduce antimicrobial resistance in DK and in the EU in the health care sector Niels Frimodt-Møller Professor, MD DMSc Dept. of Clinical Microbiology Hvidovre Hospital, Copenhagen,
More informationRational use of antibiotics
Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationImpact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study
Int J Clin harm (2012) 34:290 294 DOI 10.1007/s11096-012-9621-7 SHORT RESEARCH REORT Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study
More informationAntimicrobial Stewardship. Where are we now and where do we need to go?
Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR 2017 @SPC2016Cork Antimicrobial Stewardship. Where are we now and where do we need to go? Frank O Riordan Antimicrobial pharmacist,
More informationIDENTIFICATION: PROCESS: Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital
Waging the War against C. difficile Radical Multidisciplinary Approaches From a Community Hospital Organization Name: St. Joseph Medical Center Type: Acute Care Hospital Contact Person: Leigh Chapman RN,
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationScreening programmes for Hospital Acquired Infections
Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,
More informationECDC-EFSA-EMA Joint Opinion on Outcome Indicators on Surveillance of Antimicrobial Resistance and Use of Antimicrobials
ECDC-EFSA-EMA Joint Opinion on Outcome Indicators on Surveillance of Antimicrobial Resistance and Use of Antimicrobials P.-A. Belœil (EFSA) and D. Monnet (ECDC) One Health Network on Antimicrobial Resistance
More informationAttributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic-Resistant Gram-Negative Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2010, p. 109 115 Vol. 54, No. 1 0066-4804/10/$12.00 doi:10.1128/aac.01041-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Attributable
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01305.x Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes C. Y. Wang 1, J. S. Jerng 1, K. Y. Cheng
More informationHand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY
Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY MDROs and Hand Hygiene Guidelines HH Apr14 The Science of Hand Hygiene in Healthcare Settings
More informationTREAT Steward. Antimicrobial Stewardship software with personalized decision support
TREAT Steward TM Antimicrobial Stewardship software with personalized decision support ANTIMICROBIAL STEWARDSHIP - Interdisciplinary actions to improve patient care Quality Assurance The aim of antimicrobial
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationSection of Infectious Diseases and Clinical Microbiology, Uppsala University, Uppsala, Sweden
ORIGIL ARTICLE 1.1111/j.1469-691.27.1946.x Associated antimicrobial resistance in Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes A.
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationIs Clostridium difficile infection influenced by antimicrobial use density in wards?
Apr. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 2 87 29 Is Clostridium difficile infection influenced by antimicrobial use density in wards? NOBUMICHI OGAMI, JUNICHI YOSHIDA, TOSHIYUKI ISHIMARU, TETSUYA
More informationWorkplan on Antibiotic Usage Management
IMPACT Forum: Antibiotic Guideline in Perspective Workplan on Antibiotic Usage Management Dr. Raymond Yung Consultant Microbiologist PYNEH 20 April 2002 May 2002 Dr. Raymond Yung 1 Objective 1. Heighten
More informationNational Point Prevalence Survey of Healthcare Associated Infection, Device Usage and Antimicrobial Prescribing Wales. HCAI and AMR Programme
National Point Prevalence Survey of Healthcare Associated Infection, Device Usage and Antimicrobial Prescribing 2017 Wales HCAI and AMR Programme The Healthcare Associated Infection and Antimicrobial Resistance
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationAntimicrobial Stewardship Strategy: Formulary restriction
Antimicrobial Stewardship Strategy: Formulary restriction Restricted dispensing of targeted antimicrobials on the hospital s formulary, according to approved criteria. The use of restricted antimicrobials
More informationNational Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4606 4610 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4606 4610.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More information